Business Description
Genelux Corp
NAICS : 541714
SIC : 2834
Description
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.05 | |||||
| Equity-to-Asset | -5.22 | |||||
| Debt-to-Equity | -0.79 | |||||
| Debt-to-EBITDA | -12.47 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | -34.55 | |||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.62 | |||||
| 9-Day RSI | 67.95 | |||||
| 14-Day RSI | 67.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.13 | |||||
| Quick Ratio | 0.13 | |||||
| Cash Ratio | 0.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -30.14 | |||||
| Net Margin % | -49.56 | |||||
| ROA % | -64.81 | |||||
| ROIC % | -21.44 | |||||
| ROC (Joel Greenblatt) % | -135.58 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 85.23 | |||||
| EV-to-EBIT | -243.64 | |||||
| EV-to-EBITDA | -358.77 | |||||
| EV-to-Revenue | 66.47 | |||||
| EV-to-FCF | -673.26 | |||||
| Earnings Yield (Greenblatt) % | -0.41 |
How Genelux Corp (GNLX) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GNLX
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 11 | ||
| EPS (TTM) ($) | -0.2 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 67.62 | ||
| 14-Day ATR ($) | 4.742096 | ||
| 20-Day SMA ($) | 22.954 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 5.35 - 39.2717 | ||
| Shares Outstanding (Mil) | 23.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genelux Corp Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genelux Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Genelux Corp Frequently Asked Questions
What is Genelux Corp(GNLX)'s stock price today?
The current price of GNLX is $30.00. The 52 week high of GNLX is $39.27 and 52 week low is $5.35.
When is next earnings date of Genelux Corp(GNLX)?
The next earnings date of Genelux Corp(GNLX) is .
Does Genelux Corp(GNLX) pay dividends? If so, how much?
Genelux Corp(GNLX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
